Tobacco.org

• Genetically Stratifying Smoking-Cessation Trials Could Save Up to $15M, Researchers Find  

With genotyping costs declining and the cost of conducting conventional trials increasing, researchers from the National Institutes of Health and Duke University have modeled data suggesting it may save money to genetically stratify patients in clinical trials for smoking cessation.

In mid-sized Phase II trials enrolling around 200 patients, "there was the clearest benefit for genotyping under a wide range of assumptions, [such as] cost per subject for the trial and genotyping cost per subject," lead study author George Uhl of the National Institute on Drug Abuse, told Pharmacogenomics Reporter this week.

The findings of the study, published in The Pharmacogenomics Journal, shed light onto the circumstances in which genotyping may be cost-effective in smoking-cessation studies, and could help inform the design of studies for other addictions and disease indications, the study authors noted.

Jump to full article »